Announcement on Obtaining the "Drug Clinical Trial Approval Notification" for Innovative Drug HSK60002 Tablets

Haisco Pharmaceutical Group Co., Ltd.·August 12, 2026·2 pages

✨ AI Summary

Hansoh Pharmaceutical announced it has received the "Drug Clinical Trial Approval Notification" from the NMPA for its innovative drug HSK60002 tablets. This oral small molecule formulation is intended for inflammatory diseases. Pre-clinical studies show significant efficacy, and the drug has clear development value and good prospects for clinical application.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002653

Securities Abbreviation: Hansoh Pharma

Announcement Number: 2026-090

Hansoh Pharmaceutical Group Co., Ltd.

Announcement on Obtaining the "Drug Clinical Trial Approval Notification" for Innovative Drug HSK60002 Tablets

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.

Hansoh Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration, and the relevant situation is announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.